Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 5/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.35 |
| ▸ | HTR3B | O95264 | 2/20 | 0.35 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.35 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.35 |
| ▸ | HTR5A | P47898 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1079419 | 1.00 | SIGMAR1 (0.38) | SIGMAR1HTR3ACHRNA7HTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL13387322 | 0.99 | SIGMAR1 (0.37) | SIGMAR1HTR3ACHRNA7HTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL13387323 | 0.99 | SIGMAR1 (0.37) | SIGMAR1HTR3ACHRNA7HTR3EHTR3B | |
| SCHEMBL13387265 | 0.91 | SIGMAR1 (0.39) | SIGMAR1HTR3ACHRNA7 | |
| SCHEMBL13387268 | 0.91 | SIGMAR1 (0.39) | SIGMAR1HTR3ACHRNA7 | |
| SCHEMBL1080362 | 0.90 | SIGMAR1 (0.37) | SIGMAR1HTR3ACHRNA7HTR3EHTR3B | |
| SCHEMBL1080364 | 0.90 | SIGMAR1 (0.37) | SIGMAR1HTR3ACHRNA7HTR3EHTR3B | |
| SCHEMBL1078969 | 0.86 | CHRNA7 (0.45) | HTR3ACHRNA7 | |
| SCHEMBL1078971 | 0.86 | CHRNA7 (0.45) | HTR3ACHRNA7 | |
| SCHEMBL9231237 | 0.83 | SIGMAR1 (0.37) | SIGMAR1HTR3ACHRNA7HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045501-B2 | 5-HT3 receptor modulators, methods of making, and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140234443-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8710046-B2 | 5-HT3 receptor modulators, methods of making, and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20120270857-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| EP-2459563-A2 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | Albany Molecular Research, Inc. (US) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011008572-A2 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270857-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | HTR3A, HTR5A, HTR3B | SIGMAR1 209/4885HTR3A 1/4885CHRNA7 300/4885 |
| US-20140234443-A1 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | HTR3A, HTR5A, HTR3B | SIGMAR1 209/4885HTR3A 1/4885CHRNA7 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.